Plunkett Research Online: Transition Therapeutics Inc

TRANSITION THERAPEUTICS INC (TTHI) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. The Company's lead CNS drug candidate is ELND005 for the treatment of agitation/aggression associated with Alzheimer's disease, bipolar disorder and Down syndrome. Transition's lead m.....


TRANSITION THERAPEUTICS INC

Ticker: TTHI
Exchange: NAS
Parent Company:
Employees:
Fiscal Year Ends in

Phone: 416 260-7770
Fax: 416 260-2886
Address: 220-101 College St
Toronto, ON M5G 1L7 Canada

Types Of Business
Industry Ranks

Industry NAICS code:

ContactsDescription

Tony CruzCEO/Chairman of the Board/Director
Nicole Rusaw-GeorgeCFO
See More
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. The Company's lead CNS drug candidate is ELND005 for the treatment of agitation/aggression associated with Alzheimer's disease, bipolar disorder and Down syndrome. Transition's lead m.....See More See More

$USD, In whole numbers 2017201620152014201320122011
Sales
Profits
Brands, Divisions and AffiliatesTop Salaries
Salary
Bonus
Other ThoughtsCorporate Culture